Schizophrenia Study In Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00049946|
Recruitment Status : Completed
First Posted : November 18, 2002
Last Update Posted : August 16, 2017
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: talnetant Drug: risperidone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||231 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia|
|Study Start Date :||October 2002|
|Primary Completion Date :||April 2003|
|Study Completion Date :||April 2003|
- Change from baseline in the PANSS total score.
- Secondary measures assessed efficacy, safety & tolerability endpoints using the PANSS, BPRS Psychosis score, CGI-S, CGI-GI, Calgary Depression Scale for Schizophrenia, Brief Assessment of Cognition for Schizophrenia, and others.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00049946
Show 31 Study Locations
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|